AFC-HD AMS Life Science Co., Ltd. AI Stock Analysis
Want to see JP:2927 full AI Analyst Report?
AFC-HD AMS Life Science Co., Ltd. (2927) AI Stock Analysis
AFC-HD AMS Life Science Co., Ltd.
(TSE/TYO:2927)
The overall score is low, primarily driven by significant financial weaknesses. Persistently negative free cash flow and a highly leveraged balance sheet are major risks. Bearish technical momentum further weighs on the score. An attractive valuation and high dividend yield provide some support but are not enough to offset the fundamental concerns.
AFC-HD AMS Life Science Co., Ltd. (2927) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 12.32B
- Dividend Yield
- 4.72%
- Average Volume (3M)
- 27.59K
- Price to Earnings (P/E)
- 10.2
- Beta (1Y)
- 0.30
- Revenue Growth
- 5.11%
- EPS Growth
- -19.41%
- Country
- Japan
- Employees
- 1,008
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
AFC-HD AMS Life Science Co., Ltd. Business Overview & Revenue Model
Company Description
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The Healt...
How the Company Makes Money
The company primarily makes money by selling health-related products (e.g., supplements and other wellness products) through its commercial channels. Revenue is generated from product sales, which may include (1) branded product sales to consumers an...
AFC-HD AMS Life Science Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak. While revenue is growing, profitability is under pressure with declining margins and thin net profit. The balance sheet is highly leveraged, and cash flow is a significant concern with persistently negative free cash flow, indicating poor cash conversion and reliance on external financing.
Income Statement
58NeutralBalance Sheet
45NeutralCash Flow
25Negative| Breakdown | TTM | Aug 2026 | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.32B | 34.32B | 32.66B | 30.19B | 25.58B | 23.00B |
| Gross Profit | 11.65B | 11.65B | 10.97B | 10.49B | 9.32B | 8.58B |
| EBITDA | 3.98B | 3.92B | 3.80B | 3.10B | 2.59B | 2.30B |
| Net Income | 1.20B | 1.20B | 1.45B | 1.25B | 1.10B | 735.35M |
Balance Sheet | ||||||
| Total Assets | 49.05B | 49.05B | 48.73B | 47.03B | 41.07B | 37.35B |
| Cash, Cash Equivalents and Short-Term Investments | 9.76B | 9.76B | 11.30B | 12.17B | 11.18B | 10.38B |
| Total Debt | 23.41B | 23.41B | 24.14B | 23.40B | 19.59B | 17.24B |
| Total Liabilities | 32.61B | 32.61B | 33.53B | 33.07B | 27.91B | 24.90B |
| Stockholders Equity | 16.21B | 16.21B | 15.08B | 13.93B | 13.11B | 12.44B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -726.43M | -1.75B | -1.87B | -1.07B | 534.45M |
| Operating Cash Flow | 0 | 1.68B | 1.79B | 1.54B | 865.28M | 1.49B |
| Investing Cash Flow | 0 | -2.85B | -3.33B | -2.76B | -1.95B | -1.08B |
| Financing Cash Flow | 0 | -616.99M | 666.75M | 2.23B | 1.88B | 1.16B |
AFC-HD AMS Life Science Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2927, the sentiment is Neutral. The current price of 847.00 is below the 20-day moving average (MA) of 851.55, below the 50-day MA of 853.24, and below the 200-day MA of 848.12, indicating a bearish trend. The MACD of -3.49 indicates Positive momentum. The RSI at 48.98 is Neutral, neither overbought nor oversold. The STOCH value of 58.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2927.
AFC-HD AMS Life Science Co., Ltd. Peers Comparison
Overall Rating
JP:452679Outperform
JP:200274.15Outperform
JP:137567Neutral
JP:313966Neutral
JP:293653Neutral- JP:292748Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4526 | 79Outperform | JPY 81.29B | 15.07 | ― | 3.03% | 3.68% | -25.50% |
| JP:2002 | 74Outperform | JPY 640.52B | 16.83 | ― | 2.58% | 2.60% | 69.40% |
| JP:1375 | 67Neutral | JPY 45.06B | 11.66 | ― | 2.11% | 6.19% | 363.19% |
| JP:3139 | 66Neutral | JPY 34.74B | 9.94 | ― | 4.21% | 5.61% | -15.32% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| JP:2936 | 53Neutral | JPY 12.76B | 230.77 | ― | ― | 3.21% | -90.33% |
| JP:2927 | 48Neutral | JPY 11.92B | 10.21 | ― | 4.72% | 5.11% | -19.41% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2927 | AFC-HD AMS Life Science Co., Ltd. | 847.00 | 22.85 | 2.77% | |
| JP:1375 | YUKIGUNI MAITAKE CO., LTD. | 1140.00 | 140.33 | 14.04% | |
| JP:2002 | Nisshin Seifun Group Inc. | 2399.50 | 632.29 | 35.78% | |
| JP:2936 | BASE FOOD Inc. | 240.00 | -110.00 | -31.43% | |
| JP:3139 | Lacto Japan Co., Ltd. | 3515.00 | 10.67 | 0.30% | |
| JP:4526 | Riken Vitamin Co., Ltd. | 3635.00 | 889.76 | 32.41% |
AFC-HD AMS Life Science Co., Ltd. Corporate Events
AFC-HD AMS Life Science Posts Higher Sales but Lower Profit for FY2026
AFC-HD AMS Life Science reported consolidated net sales of ¥34,324 million for the fiscal year ended August 31, 2026, a 5.1% increase from the previous year, supported by steady operating performance that lifted operating profit slightly to ¥2,455 mi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026